An Open-Label Study to Evaluate 3 Month Corneal Endothelial Cell Density Changes in Healthy Subjects When Mapracorat Ophthalmic Suspension, 3%, is Administered 4 Times Daily for 14 Days
Latest Information Update: 03 Dec 2013
At a glance
- Drugs Mapracorat (Primary)
- Indications Allergic conjunctivitis; Atopic dermatitis; Dry eyes; Ocular inflammation; Ocular pain
- Focus Pharmacodynamics
- Sponsors Bausch & Lomb
- 03 Dec 2013 New trial record